NCT03802240 2023-11-27
Sintilimab ± IBI305 Plus Chemotherapy (Pemetrexed + Cisplatin) for EGFRm + Locally Advanced or Metastasis Non-Squamous NSCLC Patients After EGFR-TKI Treatment Failure
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Completed
Clinical Trials
8 trialsNCT02008227 2019-12-20
OAK
Hoffmann-La Roche
Phase 3 Completed
NCT01351415 2017-09-18
A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)
Hoffmann-La Roche
Phase 3 Completed
NCT01456325 2016-11-02
A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)
Genentech, Inc.
Phase 3 Completed
NCT01887886 2016-11-02
A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation
Hoffmann-La Roche
Phase 3 Completed
NCT01328951 2016-10-28
A Study of First-line Maintenance Erlotinib Versus Erlotinib at Disease Progression in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Platinum-Based Chemotherapy
Hoffmann-La Roche
Phase 3 Completed
NCT00961415 2016-02-22
AVAPERL1 Study: A Study of Avastin (Bevacizumab) With or Without Pemetrexed as Maintenance Therapy After Avastin in First Line in Patients With Non-Squamous Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed
NCT00883779 2015-12-14
A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer
Hoffmann-La Roche
Phase 3 Completed